---
title: Genetics of Recurrent Early Onset Major Depression
nct_id: NCT00260182
overall_status: COMPLETED
sponsor: Stanford University
study_type: OBSERVATIONAL
primary_condition: Depression
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00260182.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00260182"
ct_last_update_post_date: 2019-04-19
last_seen_at: "2026-05-12T06:56:23.985Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Genetics of Recurrent Early Onset Major Depression

**NCT ID:** [NCT00260182](https://clinicaltrials.gov/study/NCT00260182)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 2302
- **Lead Sponsor:** Stanford University
- **Collaborators:** National Institute of Mental Health (NIMH)
- **Conditions:** Depression
- **Start Date:** 2005-10
- **Completion Date:** 2009-06
- **CT.gov Last Update:** 2019-04-19

## Brief Summary

This study will identify specific genes that may cause a predisposition to depression in some families.

## Detailed Description

Depression is a serious medical illness that is often difficult to diagnose and treat. Studies on patterns of depression within families suggest that inherited genes may cause a predisposition to the disorder. People with early onset depression often have more relatives with depression than people whose depression does not begin until later in life. It is likely that several interacting genes cause this tendency towards the disorder, rather than one specific gene. This study will serve to identify particular genes that may cause a susceptibility to depression in order to better understand the brain mechanisms involved with severe depression. In turn, this may aid in the development of new treatments for depression.

Participation in this observational study will entail one interview and one blood test. Participants will be interviewed, either in person or by telephone, about their personal and family psychiatric history. The blood sample will be collected at a time and location that is convenient for the participant. Participants may also be asked to invite other family members to participate in the study.

For information on a related study please follow this link:

http://clinicaltrials.gov/show/NCT00005914

## Eligibility

- **Minimum age:** 21 Years
- **Maximum age:** 70 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* History of recurrent major depression
* Has a parent or sibling with a history of recurrent major depression
* Depression began before the age of 31

Exclusion Criteria:

* Bipolar I (manic-depressive) disorder
* Schizophrenia
```

## Primary Outcomes

- **Major depressive disorder diagnosis** _(time frame: One patient interview session (typically 2 hours), and blood draw (10-20 minutes))_ — The study will correlate genome-wide SNP genotypes with case vs. control status, defined by presence or absence of major depressive disorder.

Participants will attend an interview regarding personal and family history of psychiatric disorders, and give a blood specimen. Genotypes from blood samples will be studied for association with presence of major depressive disorder.

## Locations (6)

- Stanford University, Palo Alto, California, United States
- Howard University, Washington D.C., District of Columbia, United States
- Rush University Medical Center, Chicago, Illinois, United States
- University of Iowa, Iowa City, Iowa, United States
- Johns Hopkins University, Baltimore, Maryland, United States
- Columbia University/New York State Psychiatric Institute, New York, New York, United States

## Recent Field Changes (last 30 days)

- `locations.columbia university/new york state psychiatric institute|new york|new york|united states` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.stanford university|palo alto|california|united states` — added _(2026-05-12)_
- `locations.howard university|washington d.c.|district of columbia|united states` — added _(2026-05-12)_
- `locations.rush university medical center|chicago|illinois|united states` — added _(2026-05-12)_
- `locations.university of iowa|iowa city|iowa|united states` — added _(2026-05-12)_
- `locations.johns hopkins university|baltimore|maryland|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00260182.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00260182*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*